OncoMatch/Clinical Trials/NCT05200260

Surgery Combined With Maintenance Targeted Therapy in the Treatment of Advanced Ovarian Cancer

Is NCT05200260 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies multiple treatments including PARP inhibitor and Bevacizumab for ovarian cancer.

Phase 2RecruitingShanghai Gynecologic Oncology GroupNCT05200260Data as of May 2026

Treatment: PARP inhibitor · Bevacizumab — Optimal Timing of Surgery combined with Maintenance Therapy in the Front-line Treatment of Advanced Ovarian Cancer

Check if I qualify

Extracted eligibility criteria

Cancer type

Ovarian Cancer

Biomarker criteria

Required: BRCA1 any tested

Required: BRCA2 any tested

Disease stage

Required: Stage IIIC, IV

Performance status

ECOG 0–2(Ambulatory, capable of self-care)

Lab requirements

Blood counts

white blood cells >3,000/µl, absolute neutrophil count ≥1,500/µl, platelets ≥100,000/µl, hemoglobin ≥9 g/dl

Kidney function

serum creatinine <1.25 x upper normal limit (unl) or creatinine clearance ≥60 ml/min according to cockroft-gault formula or to local lab measurement

Liver function

serum bilirubin <1.25 x unl, ast(sgot) and alt(sgpt) <2.5 x unl

Structured fields extracted by AI. May contain errors — verify against the official protocol.

Could you qualify for this trial?

Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.

Check if I qualify